1677PDA phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy

ConclusionsGiven that the primary endpoint was met, these data suggest that there is a benefit to front-line pazopanib in patients who are not candidates for cytotoxic chemotherapy.Clinical trial identificationNCT02300545.Legal entity responsible for the studyWashington University in St Louis.FundingNovartis/GSK.DisclosureM. Agulnik: Advisory / Consultancy: Novartis; Advisory / Consultancy: Lilly; Advisory / Consultancy: Immune Design; Advisory / Consultancy: Bayer; Speaker Bureau / Expert testimony: Janssen; Speaker Bureau / Expert testimony: Eisai; Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Bayer. M. Varun: Travel / Accommodation / Expenses: Deciphera; Research grant / Funding (institution): Immunocellular; Research grant / Funding (institution): Orbus Therapeutics. M. Milhem: Advisory / Consultancy: Amgen; Advisory / Consultancy: Trieza; Advisory / Consultancy: Biontech; Advisory / Consultancy: Blueprint medicine cooperation; Advisory / Consultancy: Immunocore; Advisory / Consultancy: Array BioPharma, Inc. S. Robinson: Research grant / Funding (institution): TRACON; Honoraria (institution), Advisory / Consultancy: BTG International; Honoraria (institution), Advisory / Consultancy: Society of Interventional Radiology Foundation. S. Attia: Research grant / Funding (institution): AB Science; Research grant / Funding (institution): TRACON Pharma; Research grant / Funding (institution): CytRX Corporation; Research grant / Funding (institution): B...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research